Results 61 to 70 of about 39,428 (277)

Surgical Management of Recurrent Retroperitoneal Sarcomas: Experience From a High‐Volume Sarcoma Centre

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background Retroperitoneal sarcoma (RPS) is a rare and complex malignancy, requiring specialized multidisciplinary care. While a significant progress has been made in managing a primary RPS, there is a limited literature on the outcomes of recurrent RPS (RecRPS).
Abdeali Saif Arif Kaderi   +14 more
wiley   +1 more source

Neoadjuvant Systemic Treatment of Primary Angiosarcoma

open access: yesCancers, 2020
Angiosarcoma is an extremely rare and aggressive malignancy. Standard of care of localized tumors includes surgery ± radiation. Despite this multimodal treatment, >50% of the angiosarcoma patients develop local or distant recurrent disease.
K. M. Heinhuis   +7 more
semanticscholar   +1 more source

Primary and secondary angiosarcomas: a comparative single-center analysis [PDF]

open access: yes, 2015
Background: Angiosarcomas (AS) are rare vascular malignancies. They are subdivided into primary (PAS) and secondary angiosarcomas (SAS). The objective was to compare the characteristics of AS subtypes. Methods: Eighteen PAS and ten SAS patients treated
Hillenbrand, Thorsten   +3 more
core   +1 more source

A pooled analysis of primary hepatic angiosarcoma.

open access: yesJapanese Journal of Clinical Oncology, 2020
BACKGROUND Angiosarcoma is an aggressive and malignant neoplasm. Primary hepatic angiosarcoma is extremely rare and accounts for only approximately 5% of all angiosarcomas.
D. Zeng   +5 more
semanticscholar   +1 more source

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

open access: yesThe Journal of Pathology, EarlyView.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov   +6 more
wiley   +1 more source

Clinicopathological characteristics and survival outcomes in patients with angiosarcoma of breast

open access: yesCancer Medicine, 2023
Background Angiosarcoma of the breast is a rare malignancy. There are little data evaluating the survival and estimating the prognostic factors. The best surgical management and the role of systemic adjuvant therapy remain ill‐defined.
Junfeng Li   +6 more
doaj   +1 more source

An Autopsy Case of Ruptured Hepatic Angiosarcoma Treated by Transcatheter Arterial Embolization

open access: yesCase Reports in Gastroenterology, 2023
An 80-year-old Japanese man presented to our hospital with intra-abdominal hemorrhage due to a ruptured liver tumor. Transcatheter arterial embolization (TAE) temporarily achieved hemostasis, but he died following re-rupture 4 days later.
Toshiki Entani   +6 more
doaj   +1 more source

Primary temporal bone angiosarcoma: a case report. [PDF]

open access: yes, 2005
We present a rare case of temporal bone angiosarcoma diagnosed in a 26-year-old female patient at 36 week of pregnancy. The patient was referred with a 2 months history of left otalgia and tinnitus with a tender swelling above the mastoid.
C Antoniadis   +27 more
core   +1 more source

Primary renal angiosarcoma mimicking urothelial carcinoma – A case report and literature reviews

open access: yesUrology Case Reports, 2021
Angiosarcoma (AS) is a rare aggressive tumor originating from endothelial cells. We reported a 66-year-old female with primary renal angiosarcoma (PRA) who presented as urothelial carcinoma with hematuria and dysuria.
Che-Wei Chang   +3 more
doaj   +1 more source

Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update [PDF]

open access: yes, 2017
Summary: Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents.
A Alvarado-Miranda   +31 more
core   +1 more source

Home - About - Disclaimer - Privacy